Matches in SemOpenAlex for { <https://semopenalex.org/work/W2349202816> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2349202816 abstract "Objective To investigate the risk factors for hepatocellular carcinoma (HCC) in patients with hepatitis B-related decompensated cirrhosis and the optimization of antiviral therapy.Methods Totally 193 patients with hepatitis B-related decom-pensated cirrhosis treated in our hospital from Jan.2008 to Oct.2011,who were followed up for two years,were included in the study,including 29 receiving LAM therapy (LAM group),57 receiving ADV therapy (ADV group),30 receiving LDT therapy (LDT group),38 receiving ETV therapy (ETV group) and 39 not receiving any antiviral therapy (control group).According to whether drug resis-tance occurred before being diagnosed with HCC,the patients receiving antiviral therapy were divided into drug-resistant group (n=31) and non-drug-resistant group (n=123).Child-Pugh scores,virological markers,the incidence of HCC,survival rate and safety were analyzed.Results Child-Pugh scores in each antiviral therapy group significantly decreased at 2-year follow-up,compared with those at baseline (P0.05).HBV DNA level of each antiviral group during 2-year follow-up was significantly lower than that at baseline,and the differences in the rates of HBV DNA undetectable in each group weren't significant.HBeAg seroconversion rate and negative conversion rate of each antiviral group during 2-year follow-up were not significantly different.Cumulative drug-resis-tant rate at 2-year follow-up in ETV group was lower than those in LAM,ADV and LDT groups (P0.05).Cumulative incidence of HCC and survival rates were not significantly different between each antiviral therapy group and the control group.However,the incidence of HCC of drug-resistant group was significantly higher than that of non-drug-resistant group and the control group (P0.05).No adverse reactions such as severe cardiomyopathy were found in each antiviral therapy group during 2-year follow-up.Conclusions The effi-cacy of ETV therapy is superior to that of LAM,ADV and LDT therapy in patients with hepatitis B-related decompensated cirrhosis,and antiviral drug resistance may increase the incidence of HCC." @default.
- W2349202816 created "2016-06-24" @default.
- W2349202816 creator A5088981302 @default.
- W2349202816 date "2012-01-01" @default.
- W2349202816 modified "2023-09-28" @default.
- W2349202816 title "Increased incidence of hepatocellular carcinoma due to antiviral drug resistance in patients with hepatitis B-related decompensated cirrhosis" @default.
- W2349202816 hasPublicationYear "2012" @default.
- W2349202816 type Work @default.
- W2349202816 sameAs 2349202816 @default.
- W2349202816 citedByCount "0" @default.
- W2349202816 crossrefType "journal-article" @default.
- W2349202816 hasAuthorship W2349202816A5088981302 @default.
- W2349202816 hasConcept C120665830 @default.
- W2349202816 hasConcept C121332964 @default.
- W2349202816 hasConcept C126322002 @default.
- W2349202816 hasConcept C203014093 @default.
- W2349202816 hasConcept C2522874641 @default.
- W2349202816 hasConcept C2775940106 @default.
- W2349202816 hasConcept C2776175608 @default.
- W2349202816 hasConcept C2777214474 @default.
- W2349202816 hasConcept C2777382497 @default.
- W2349202816 hasConcept C2777410769 @default.
- W2349202816 hasConcept C2777451964 @default.
- W2349202816 hasConcept C2777869810 @default.
- W2349202816 hasConcept C2778019345 @default.
- W2349202816 hasConcept C2780593183 @default.
- W2349202816 hasConcept C2993512173 @default.
- W2349202816 hasConcept C3020491458 @default.
- W2349202816 hasConcept C61511704 @default.
- W2349202816 hasConcept C71924100 @default.
- W2349202816 hasConcept C72563966 @default.
- W2349202816 hasConcept C88879693 @default.
- W2349202816 hasConcept C90924648 @default.
- W2349202816 hasConceptScore W2349202816C120665830 @default.
- W2349202816 hasConceptScore W2349202816C121332964 @default.
- W2349202816 hasConceptScore W2349202816C126322002 @default.
- W2349202816 hasConceptScore W2349202816C203014093 @default.
- W2349202816 hasConceptScore W2349202816C2522874641 @default.
- W2349202816 hasConceptScore W2349202816C2775940106 @default.
- W2349202816 hasConceptScore W2349202816C2776175608 @default.
- W2349202816 hasConceptScore W2349202816C2777214474 @default.
- W2349202816 hasConceptScore W2349202816C2777382497 @default.
- W2349202816 hasConceptScore W2349202816C2777410769 @default.
- W2349202816 hasConceptScore W2349202816C2777451964 @default.
- W2349202816 hasConceptScore W2349202816C2777869810 @default.
- W2349202816 hasConceptScore W2349202816C2778019345 @default.
- W2349202816 hasConceptScore W2349202816C2780593183 @default.
- W2349202816 hasConceptScore W2349202816C2993512173 @default.
- W2349202816 hasConceptScore W2349202816C3020491458 @default.
- W2349202816 hasConceptScore W2349202816C61511704 @default.
- W2349202816 hasConceptScore W2349202816C71924100 @default.
- W2349202816 hasConceptScore W2349202816C72563966 @default.
- W2349202816 hasConceptScore W2349202816C88879693 @default.
- W2349202816 hasConceptScore W2349202816C90924648 @default.
- W2349202816 hasLocation W23492028161 @default.
- W2349202816 hasOpenAccess W2349202816 @default.
- W2349202816 hasPrimaryLocation W23492028161 @default.
- W2349202816 hasRelatedWork W1985624846 @default.
- W2349202816 hasRelatedWork W1999253578 @default.
- W2349202816 hasRelatedWork W2009474584 @default.
- W2349202816 hasRelatedWork W2012585388 @default.
- W2349202816 hasRelatedWork W2119585821 @default.
- W2349202816 hasRelatedWork W2120058397 @default.
- W2349202816 hasRelatedWork W2366298905 @default.
- W2349202816 hasRelatedWork W2367227056 @default.
- W2349202816 hasRelatedWork W2370095061 @default.
- W2349202816 hasRelatedWork W2371053136 @default.
- W2349202816 hasRelatedWork W2414424144 @default.
- W2349202816 hasRelatedWork W2603780706 @default.
- W2349202816 hasRelatedWork W2993004904 @default.
- W2349202816 hasRelatedWork W3032090237 @default.
- W2349202816 hasRelatedWork W3037193047 @default.
- W2349202816 hasRelatedWork W3149382726 @default.
- W2349202816 hasRelatedWork W3161330287 @default.
- W2349202816 hasRelatedWork W3162781171 @default.
- W2349202816 hasRelatedWork W3180122705 @default.
- W2349202816 hasRelatedWork W3206217124 @default.
- W2349202816 isParatext "false" @default.
- W2349202816 isRetracted "false" @default.
- W2349202816 magId "2349202816" @default.
- W2349202816 workType "article" @default.